Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
deals
3
×
ipo
3
×
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
boston top stories
cancer
clinical trials
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco
sanofi
startups
third rock ventures
venture capital
warp drive bio
abbvie
acetylon pharmaceuticals
akouos
allergan
alnylam pharmaceuticals
amag pharmaceuticals
ambys medicines
amgen
amunix
anirvan ghosh
astrazeneca
biogen
bluerock therapeutics
boulder/denver blog main
boulder/denver top stories
cancer drugs
cancer immunotherapy
cell therapy
What
medicines
3
×
deal
ipo
acquisitions
aiming
ambys
announced
big
bio
biotech
cancer
ceo
collabs
control
covid
daniel
deadly
debuted
despite
diseases
drug
family
formed
future
gilead
gilead’s
hardest
help
hit
hottest
hunters
introduce
launch
liver
make
month
new
o’day
plans
proteins
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?